CN110302431A - A kind of injectable type bioactivity glass of the DBM containing decalcified bone matrix and its preparation method and application - Google Patents
A kind of injectable type bioactivity glass of the DBM containing decalcified bone matrix and its preparation method and application Download PDFInfo
- Publication number
- CN110302431A CN110302431A CN201910543542.6A CN201910543542A CN110302431A CN 110302431 A CN110302431 A CN 110302431A CN 201910543542 A CN201910543542 A CN 201910543542A CN 110302431 A CN110302431 A CN 110302431A
- Authority
- CN
- China
- Prior art keywords
- dbm
- bioactivity glass
- bone matrix
- glass
- decalcified bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011521 glass Substances 0.000 title claims abstract description 80
- 210000002805 bone matrix Anatomy 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000007791 liquid phase Substances 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 19
- 239000005313 bioactive glass Substances 0.000 claims abstract description 18
- 239000007790 solid phase Substances 0.000 claims abstract description 18
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims abstract description 6
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims abstract description 6
- 239000006210 lotion Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 229910052712 strontium Inorganic materials 0.000 claims description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 8
- 239000007788 liquid Substances 0.000 abstract description 5
- 230000008439 repair process Effects 0.000 abstract description 4
- 206010061363 Skeletal injury Diseases 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 2
- 230000000278 osteoconductive effect Effects 0.000 abstract 1
- 230000002138 osteoinductive effect Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 description 31
- 230000007547 defect Effects 0.000 description 7
- 238000005303 weighing Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 102000003712 Complement factor B Human genes 0.000 description 2
- 108090000056 Complement factor B Proteins 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- KKCBUQHMOMHUOY-UHFFFAOYSA-N Na2O Inorganic materials [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 2
- 241000973495 Odax pullus Species 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 229910052681 coesite Inorganic materials 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229910052906 cristobalite Inorganic materials 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- -1 dissolution Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000002241 glass-ceramic Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 210000004663 osteoprogenitor cell Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052682 stishovite Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229910052905 tridymite Inorganic materials 0.000 description 2
- 208000010266 Aggressive Periodontitis Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- AFCIMSXHQSIHQW-UHFFFAOYSA-N [O].[P] Chemical compound [O].[P] AFCIMSXHQSIHQW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000287 alkaline earth metal oxide Inorganic materials 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 201000006727 periodontosis Diseases 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000009418 renovation Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/10—Ceramics or glasses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention belongs to bone injuries to repair biomedical materials field, and in particular to a kind of preparation method and application of the injectable type bioactivity glass of the DBM containing decalcified bone matrix.The injectable type bioactivity glass is combined by solid phase and liquid phase two parts, wherein solid phase is mixed by bioactive glass powder with DBM in proportion, and the mass ratio of bioactive glass powder and DBM are 3:1；Liquid phase is carboxymethylcellulose sodium solution, and concentration is 5 ~ 20wt%；The mass ratio of solid phase and liquid phase is 2:1 ~ 1:2；Solid phase is transferred in syringe after mixing with liquid phase by solid-to-liquid ratio.The injectable type bioactivity glass of the DBM provided by the present invention containing decalcified bone matrix has good injection-type, anti-collapsibility, osteoconductive, osteoinductive, cell activity and preferable biological degradability, is suitable for bone injury reparation.
Description
Technical field
The invention belongs to bone injuries to repair biomedical materials field, and in particular to a kind of DBM's containing decalcified bone matrix can
Injection-type bioactivity glass and its preparation method and application.
Background technique
Clinically bone defect patient is caused to increase due to astogeny, tumour, wound, osteomyelitis and bone disease etc. year by year
Add, the demand to bone impairment renovation material increasingly increases.Traditional Bone Defect Repari mode mainly includes the shifting of autologous bone and allograph bone
Plant, but there are immunological rejection, supply source it is limited and the problems such as need second operation.With the development of biomaterial, people
Work repair materials are concerned.Bioactivity glass application form multiplicity, compared to blocks repair materials, bioactivity glass
(Bioglass, BG) has good mobility, biocompatibility, bioactivity and machinability.Bioactivity glass is general
Contain CaO, P2O5, partially contain SiO2、MgO、K2O、Na2O etc., glass network are made of oxygen-octahedron or phosphorus oxygen tetrahedron,
And alkalies and alkaline earth oxide is network adjusting body, is connected between Network former by bridging oxygen, non-bridging oxygen then connects
The ratio of Network former and network adjusting body atom, bridging oxygen and non-bridging oxygen determines the bioactivity of glass.
Hench professor is based on SiO in early 1970s2-Na2O-CaO-P2O5System develops 45S5 biology for the first time
Glass (trade name:), its chemical composition is similar to bone, shows good bio-compatible after being implanted into organism
Property, this is the filling material of bone for developing bio-vitric class for the first time.From the 1st bio-vitric product in 1985Success
Since listing and being clinically used for ear bones strand displacement, bio-vitric has the clinical application history of more than ten years, and success rate is up to
90%.The Kokubo of nineteen eighty-two Kyoto Univ Japan has developed new A-W glass ceramics (trade name on forefathers' Research foundation) it is used for the Bone Defect Repari treatment at the weight bearing such as clinical backbone, hip joint position.Develop more in bioactivity glass
Mature system is Na2O-CaO-SiO2-P2O5System, i.e. 45S5 bio-vitric, representing composition is (mass fraction): 45%
SiO2, 24.5%Na2O, 24.5%CaO and 6.5%P2O5.The defect of this bio-vitric implantation people's bone, glass in 30 days
Glass is firmly chemically combined with bon e formation.1st is to send out for 1993 using granular pattern 45S5 as the bio-vitric product of constituent
It sellsMandibular defect caused by for repairing because of periodontosis.1st granular pattern for orthopaedics in 1999
45S5 bio-vitric(NovaBone) authenticates investment European market by CE, for the reparation of non-bearing bone, and in
Enter American market through FDA approval within 2000.It is 2006, first using granular pattern S53P4 as the bio-vitric of constituentIt is authenticated in Europe by CE, the replacement therapy for clinical autologous bone transplanting.What recent domestic was developed
Bio-vitric class product increasingly increases, Inion BioRestoreTM、PLUSTM
Sphere、glass-ceramics、StronBoneTM、DermaFuseTM/
MirragenTM、BG MORSELS、Equal products come out one after another and are applied to each of Bone Defect Repari
Kind direction." the bio-vitric filling material of bone " of domestic Shanghai Nuo Bang Biotechnology Co., Ltd exploitation also belongs to 45S5 biology glass
Glass is mainly used for the Bone Defect Repari of non-weight bearing area.
Bioactivity glass is likely to form interconnected three dimensional pore structures in the filling process, is conducive to bone tissue
It grows into and angiogenesis.Voids content, distribution and size in material etc. have great influence to skeletonization and at blood vessel.Biology
The phosphate groups on activity glass surface can also become the site of load bone growth factor.Decalcified bone matrix
(Demineralized BoneMatrix, DBM) is the production that chilled homogeneous allogenic bone, degreasing, decalcification, deproteinized are handled
Object remains the matrix such as the growth factor that can induce bone tissue formation and collagen.The growth factor B MP that DBM is released can be situated between
Guided cell sticks, and activation signal conduction path, make from periosteum fibrous layer, have around blood vessel and in soft tissue multipotency and
The inductivity osteoprogenitor cells of Multidirectional Differentiation feature is converted to cartilage, osteoblast direction, realizes induced osteogenesis.
On the basis of keeping the good degradation property of bioactive glass powder and bone conduction effect, addition has the present invention
On the one hand the DBM of osteogenic induction ability increases the structure of bioactivity glass lotion loose and porous inner surface, after another aspect decalcification
Soft light DBM can partially increase injection property.Thick liquid is formed after CMC molecular melting in liquid phase, can be increased
The injection property and anti-collapsibility performance of bio-vitric slurry reduce the wind that bioactive glass powder causes embolism with blood flow
Danger.Solid phase is packed into syringe after mixing with liquid phase, and the intracorporal various composition of bioactivity glass cream does not occur to be similar to bone water
The curing reaction of mud, save still can smoothly inject for a long time, be convenient for clinical use.In this way building load bone uptake because
Son (DBM), the bioactivity glass product with good degradation property, can preferably meet clinical demand, benefit patient, also have
There is good social and economic benefit.
Summary of the invention
The present invention is in view of the deficiencies of the prior art, and it is an object of the present invention to provide the injectable type of DBM containing decalcified bone matrix a kind of is raw
Object activity glass and its preparation method and application.
For achieving the above object, the technical scheme adopted by the invention is as follows:
A kind of injectable type bioactivity glass of the DBM containing decalcified bone matrix, is made of solid phase and liquid phase two parts, described
Solid phase is combined by bioactive glass powder and DBM, and the liquid phase part is carboxymethylcellulose sodium solution.
In above scheme, the mass ratio of the bioactive glass powder and DBM are 3:1~1:1.
In above scheme, the mass ratio of the solid phase and liquid phase is 2:1~1:2.
In above scheme, the bioactive glass powder is selected from 45S5 bioactivity glass, S53P4 bioactivity glass
One of glass, bioactivity glass containing magnesium, bioactivity glass containing strontium and boracic bioactivity glass are a variety of.
In above scheme, the partial size of the bioactive glass powder is 4~300 μm.
In above scheme, the pattern of the bioactive glass powder is spherical, ellipsoid, sheet or threadiness.
In above scheme, the size of the DBM is 100~1200 μm.
In above scheme, the pattern of the DBM is spherical, sheet or strip.
In above scheme, the concentration of the carboxymethylcellulose sodium solution is 5~20wt%.
In above scheme, the viscosity coefficient of the carboxymethylcellulose sodium solution is 8000~12000mPa.s.
The preparation method of the injectable type bioactivity glass of the above-mentioned DBM containing decalcified bone matrix, includes the following steps: to give birth to
Object activity glass powder and DBM are uniformly mixed to form solid phase, stir and evenly mix solid phase and liquid phase part to form bioactivity glass
Then lotion is transferred to the injectable type bioactivity glass obtained in syringe containing decalcified bone matrix by lotion.
Beneficial effects of the present invention: 1) present invention utilizes the collective effect of bioactivity glass and DBM, bioactivity glass
On the basis of playing bone conduction effect, calcium source and phosphorus source can be provided for new bone growth；The growth factor B MP- that DBM is released
2 can induce osteoprogenitor cells to convert to cartilage, osteoblast direction, realize bone inductive effect；Meanwhile DBM increases bioactivity
Internal gap structure, improves its degradation property, enhances the bone conduction effect of bioactivity glass after Glass syringe；Carboxylic first
Base sodium cellulosate solution can increase the injection property and anti-collapsibility performance of bioactivity glass, reduce bioactive glass particle with
Blood flow causes the risk of embolism.2) bioactivity glass of the present invention containing decalcified bone matrix (DBM) has biofacies
The feature that capacitive is good, degradability is good, bone formation performance is good can preferably meet clinical demand.
Detailed description of the invention
Fig. 1 is the injectivity and anti-collapsibility of the bioactivity glass containing DBM.
Fig. 2 is the XRD analysis of the bioactivity glass containing DBM.
Fig. 3 is the HE stained slice (rat) of the et al. Ke of bioactivity glass containing DBM test.
Specific embodiment
For a better understanding of the present invention, below with reference to the embodiment content that the present invention is furture elucidated, but it is of the invention
Content is not limited solely to the following examples.
In following embodiment, the bioactivity glass is commercially available pharmaceutical grade bioactivity glass；The decalcification bone base
Matter (DBM) is commercially available or homemade decalcified bone matrix；
Embodiment 1
One kind containing the injectable type bioactivity glass of decalcified bone matrix (DBM), is prepared via a method which to obtain:
(1) weighing viscosity coefficient is 12000mPa.s sodium carboxymethylcellulose 8g, is added in 100ml deionized water, dissolution,
Liquid phase is obtained, room temperature preservation is spare；
(2) partial size is existed for 10 μm of 45S5 bioactivity glass and the DBM 2:1 in mass ratio having a size of 800 μm of sheets
It is uniformly mixed in small mortar, then pressing solid-to-liquid ratio is 2:1 accurate weighing liquid phase, and liquid phase is added in solid phase powder, is stirred rapidly
The injectable type bioactivity glass containing decalcified bone matrix (DBM) is obtained after even after syringe.
Embodiment 2
One kind containing the injectable type bioactivity glass of decalcified bone matrix (DBM), is prepared via a method which to obtain:
(1) weighing viscosity coefficient is 8000mPa.s sodium carboxymethylcellulose 10g, is added in 100ml deionized water, dissolution,
Liquid phase is obtained, room temperature preservation is spare；
(2) by partial size be 4 μm 45S5 bioactivity glass and DBM 2:1 in mass ratio having a size of 800 μm of sheets small
It is uniformly mixed in mortar, then pressing solid-to-liquid ratio is 2:1 accurate weighing liquid phase, and liquid phase is added in solid phase powder, is stirred evenly rapidly
The injectable type bioactivity glass containing decalcified bone matrix (DBM) is obtained after syringe afterwards.
Embodiment 3
One kind containing the injectable type bioactivity glass of decalcified bone matrix (DBM), is prepared via a method which to obtain:
(1) weighing viscosity coefficient is 10000mPa.s sodium carboxymethylcellulose 15g, is added in 100ml deionized water, molten
Solution, obtains liquid phase, room temperature preservation is spare；
(2) partial size is existed for 40 μm of 45S5 bioactivity glass and the DBM 2:1 in mass ratio having a size of 800 μm of sheets
It is uniformly mixed in small mortar, then pressing solid-to-liquid ratio is 2:1 accurate weighing liquid phase, and liquid phase is added in solid phase powder, is stirred rapidly
The injectable type bioactivity glass containing decalcified bone matrix (DBM) is obtained after even after syringe.
The sample of injectable type bioactivity glass of the present invention preparation gained containing decalcified bone matrix (DBM) is injected
Performance and anti-collapsibility performance test (see Fig. 1), bioactivity glass can be injected smoothly and keep shape for a long time as the result is shown
It is not defeated and dispersed.XRD analysis (see Fig. 2) is carried out to after the sample drying of injectable type bioactivity glass, it is raw in sample as the result is shown
The peak of object activity glass is in disperse shape, it was demonstrated that and the bioactivity glass in sample still keeps amorphous state during preparing and saving,
The slightly solubility crystalline state substance of hydroxy apatites is not formed, this is conducive to improve the drop of bioactivity glass in vivo
Solve performance.Rat calvarial Implantation Test is carried out to the sample of injectable type bioactivity glass, is sampled after 4 weeks, blood routine detection
As a result normal, HE stained slice is merged in skull defeci position green bone tissue with bioactivity glass well as the result is shown, cranium
There are a large amount of freshman bone tissues to generate on the inside of bone, the skeletonization of high-visible marshalling is thin between green bone tissue and freshman bone tissue
Born of the same parents；Bioactivity glass Partial digestion, undegradable bioactive glass particle are shown as white on HE slice after decalcification
Spherical blank is distributed a large amount of connective tissues around undegradable bioactive glass particle, is distributed between connective tissue new
Angiogenic, new vessels can provide nutriment for growing into for freshman bone tissue, illustrate that the regional organization is in the early stage of skeletonization
Stage.
Obviously, above-described embodiment is only intended to clearly illustrate made example, and is not the limitation to embodiment.It is right
For those of ordinary skill in the art, can also make on the basis of the above description it is other it is various forms of variation or
It changes.There is no necessity and possibility to exhaust all the enbodiments.And the obvious variation or change therefore amplified
It moves within still in the protection scope of the invention.
Claims (10)
1. the injectable type bioactivity glass of DBM containing decalcified bone matrix a kind of, which is characterized in that by solid phase and liquid phase two parts
Composition, the solid phase are combined by bioactive glass powder and DBM by certain mass ratio, and the liquid phase is that carboxymethyl is fine
Tie up plain sodium solution.
2. the injectable type bioactivity glass of the DBM containing decalcified bone matrix according to claim 1, which is characterized in that described
The mass ratio of bioactive glass powder and DBM are 3: 1 ~ 1: 1.
3. the injectable type bioactivity glass of the DBM containing decalcified bone matrix according to claim 1, which is characterized in that described
The mass ratio of solid phase and liquid phase is 2: 1 ~ 1: 2.
4. the injectable type bioactivity glass of the DBM containing decalcified bone matrix according to claim 1, which is characterized in that described
Bioactive glass powder is selected from 45S5 bioactivity glass, S53P4 bioactivity glass, bioactivity glass containing magnesium, contains strontium
One of bioactivity glass and boracic bioactivity glass are a variety of.
5. the injectable type bioactivity glass of the DBM containing decalcified bone matrix according to claim 1, which is characterized in that described
The partial size of bioactive glass powder is 4 ~ 300 μm.
6. the injectable type bioactivity glass of the DBM containing decalcified bone matrix according to claim 1, which is characterized in that described
The pattern of bioactive glass powder is spherical, ellipsoid, sheet or threadiness.
7. the injectable type bioactivity glass of the DBM containing decalcified bone matrix according to claim 1, which is characterized in that described
The size of DBM is 100 ~ 1200 μm.
8. the injectable type bioactivity glass of the DBM containing decalcified bone matrix according to claim 1, which is characterized in that described
The pattern of DBM is spherical, sheet or strip.
9. the injectable type bioactivity glass of the DBM containing decalcified bone matrix according to claim 1, which is characterized in that described
The concentration of carboxymethylcellulose sodium solution is 5 ~ 20wt%, the viscosity coefficient of the carboxymethylcellulose sodium solution is 8000 ~
12000 mPa.s。
10. the preparation method of the injectable type bioactivity glass of any DBM containing decalcified bone matrix of claim 1 ~ 9,
It is characterized in that, includes the following steps: bioactive glass powder and DBM being uniformly mixed to form solid phase, by solid phase and liquid phase
Part stirs and evenly mixs to form bioactivity glass lotion, then will obtain in lotion syringe containing the injectable containing decalcified bone matrix
Type bioactivity glass.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910543542.6A CN110302431A (en) | 2019-06-21 | 2019-06-21 | A kind of injectable type bioactivity glass of the DBM containing decalcified bone matrix and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910543542.6A CN110302431A (en) | 2019-06-21 | 2019-06-21 | A kind of injectable type bioactivity glass of the DBM containing decalcified bone matrix and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110302431A true CN110302431A (en) | 2019-10-08 |
Family
ID=68077718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910543542.6A Pending CN110302431A (en) | 2019-06-21 | 2019-06-21 | A kind of injectable type bioactivity glass of the DBM containing decalcified bone matrix and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110302431A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112023120A (en) * | 2020-09-10 | 2020-12-04 | 湖北联结生物材料有限公司 | Injectable pre-filled bone repair particle and preparation method and application thereof |
| CN113511811A (en) * | 2021-03-16 | 2021-10-19 | 浙江大学 | A kind of multifunctional mesoporous biological material, preparation method and application |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2280745A1 (en) * | 1997-03-13 | 1998-09-17 | John F. Wironen | Bone paste |
| CN101264340A (en) * | 2007-03-15 | 2008-09-17 | 肌骨胳移植基金会 | Ceramic composition for filling bone defects |
| CN101622018A (en) * | 2006-09-06 | 2010-01-06 | 库拉森股份公司 | Phase- and sedimentation-stable, plastically deformable preparation with intrinsic pore forming, intended for example for filling bone defects or for use as bone substitute material, and method of pro |
| CN102802684A (en) * | 2009-06-26 | 2012-11-28 | Cg生物技术有限公司 | Bone-repair composition |
| CN102813962A (en) * | 2012-07-12 | 2012-12-12 | 同济大学 | Injectable and degradable bone cement, and preparation method and application thereof |
| CN108379652A (en) * | 2018-04-28 | 2018-08-10 | 湖北联结生物材料有限公司 | Have both induced degradation characteristic bone cement and preparation method thereof |
-
2019
- 2019-06-21 CN CN201910543542.6A patent/CN110302431A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2280745A1 (en) * | 1997-03-13 | 1998-09-17 | John F. Wironen | Bone paste |
| CN101622018A (en) * | 2006-09-06 | 2010-01-06 | 库拉森股份公司 | Phase- and sedimentation-stable, plastically deformable preparation with intrinsic pore forming, intended for example for filling bone defects or for use as bone substitute material, and method of pro |
| CN101264340A (en) * | 2007-03-15 | 2008-09-17 | 肌骨胳移植基金会 | Ceramic composition for filling bone defects |
| CN102802684A (en) * | 2009-06-26 | 2012-11-28 | Cg生物技术有限公司 | Bone-repair composition |
| CN102813962A (en) * | 2012-07-12 | 2012-12-12 | 同济大学 | Injectable and degradable bone cement, and preparation method and application thereof |
| CN108379652A (en) * | 2018-04-28 | 2018-08-10 | 湖北联结生物材料有限公司 | Have both induced degradation characteristic bone cement and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| XU CUI: "Evaluation of an injectable bioactive borate glass cement to heal bone", 《MATERIALS SCIENCE AND ENGINEERING C》 * |
| 张雅丽: "注射式DBM/HA-TCP复合材料研究", 《医药卫生科技辑》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112023120A (en) * | 2020-09-10 | 2020-12-04 | 湖北联结生物材料有限公司 | Injectable pre-filled bone repair particle and preparation method and application thereof |
| CN113511811A (en) * | 2021-03-16 | 2021-10-19 | 浙江大学 | A kind of multifunctional mesoporous biological material, preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106310381B (en) | A kind of calcium sulfate porous compound bio bracket of the degradable calcium phosphate-containing magnesium | |
| Weir et al. | Human bone marrow stem cell-encapsulating calcium phosphate scaffolds for bone repair | |
| CN1323986C (en) | Method for preparing CaO-P2O5-MgO glass reinforced porous beta-tricalcium phosphate bioceramics | |
| CN104056305B (en) | A kind of calcium orthophosphate base is combined self-curing bone renovating material and preparation method thereof | |
| CN102294049B (en) | Bioactive glass and chitosan composite bone repair material and preparation method and application thereof | |
| CN101695584A (en) | Injectable composite material capable of promoting bone regeneration and repair and preparation method thereof | |
| CN104644455B (en) | A kind of bio-vitric sodium alginate composite biological material and kit and application | |
| CN102058902B (en) | Method for preparing mesh-shaped bionic bone porous stent material | |
| Chen et al. | Injectable calcium sulfate/mineralized collagen‐based bone repair materials with regulable self‐setting properties | |
| CN111840652B (en) | Bone repair material and preparation method thereof | |
| CN103845762B (en) | Method for preparing porous bone scaffold by laser and increasing performance by adding zinc oxide | |
| CN103841980A (en) | Biocompatible material and uses thereof | |
| CN102430149A (en) | Boron phosphate glass fiber/chitosan composite material | |
| CN105770996A (en) | Ceramic matrix degradable artificial bone biomaterial for 3D printing | |
| Li et al. | Bioglass for skin regeneration | |
| CN112190762B (en) | An injection-type magnesium-based composite fiber reinforced calcium phosphate biological bone adhesive and its preparation method and application | |
| CN110302431A (en) | A kind of injectable type bioactivity glass of the DBM containing decalcified bone matrix and its preparation method and application | |
| CN101050053B (en) | Method for preparing engineering material of bone tissue and application | |
| CN104771782A (en) | A kind of material β-tricalcium phosphate for bone repair and its preparation method | |
| CN100591365C (en) | Inorganic resorbable bone substitute material | |
| CN107158465B (en) | Preparation method of bone scaffold composite material | |
| CN112076350A (en) | Biomimetic mineralized hydrogel with nano-micron composite structure and high mineral density as well as preparation method and application thereof | |
| CN102626526A (en) | Novel active absorbable bone cement material | |
| CN110201228A (en) | A kind of calcium phosphate bone cement and its preparation method and application containing decalcified bone matrix | |
| CN108530052A (en) | A method of utilizing gel effect 3D printing people's ceramic artificial bone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191008 |
|
| RJ01 | Rejection of invention patent application after publication |